We are live on ! Find out more
CG

Carlyle Group Portfolio holdings

AUM $10.6B
1-Year Est. Return 11.25%
This Fund
S&P 500
This Quarter Est. Return
+3.42%
1 Year Est. Return
+11.25%
3 Year Est. Return
-0.47%
5 Year Est. Return
-4.92%
10 Year Est. Return
+7.54%
AUM
$2.81B
AUM Growth
-$545M
Cap. Flow
-$547M
Cap. Flow %
-19.48%
Top 10 Hldgs %
96.38%
Holding
30
New
–
Increased
3
Reduced
3
Closed
4

Top Buys

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$6.48M
2
OKUR
OnKure Therapeutics
OKUR
+$5.04M
3
SMHI icon
SEACOR Marine Holdings
SMHI
+$1.07K

Top Sells

Rank Stock Value
1
MKSI icon
MKS Inc
MKSI
+$458M
2
PCVX icon
Vaxcyte
PCVX
+$72.1M
3
LSI
Life Storage, Inc.
LSI
+$11.3M
4
GETY icon
Getty Images
GETY
+$11M
5
VERA icon
Vera Therapeutics
VERA
+$4.91M

Sector Composition

Rank Sector Weight
1 Technology 48.16%
2 Healthcare 44.89%
3 Consumer Staples 3.58%
4 Communication Services 1.73%
5 Real Estate 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QDEL icon
1
QuidelOrtho
QDEL
$1.19B
$1.03B 36.78%
12,460,183
– –
GTM
2
ZoomInfo Technologies
GTM
$905M
$931M 33.16%
36,662,469
– –
MKSI icon
3
MKS Inc
MKSI
$21.9B
$376M 13.41%
3,482,732
-5,000,000
-59% -$458M
VTRU
4
DELISTED
Vitru Limited Common Shares
VTRU
$100M 3.57%
6,246,471
– –
VRNA
5
DELISTED
Verona Pharma
VRNA
$51.9M 1.85%
2,457,500
– –
PHAT icon
6
Phathom Pharmaceuticals
PHAT
$873M
$50.1M 1.78%
3,496,808
+561,702
+19% +$6.48M
GETY icon
7
Getty Images
GETY
$216M
$48.7M 1.73%
9,976,300
-1,926,517
-16% -$11M
GDS icon
8
GDS Holdings
GDS
$6.24B
$44.8M 1.59%
4,072,624
– –
VERA icon
9
Vera Therapeutics
VERA
$2.76B
$38.8M 1.38%
2,416,837
-543,394
-18% -$4.91M
HLVX
10
DELISTED
HilleVax
HLVX
$31.5M 1.12%
1,838,486
– –
OKUR
11
OnKure Therapeutics
OKUR
$170M
$17.7M 0.63%
269,896
+62,500
+30% +$5.04M
INVH icon
12
Invitation Homes
INVH
$17.9B
$16.4M 0.59%
477,500
– –
SMHI icon
13
SEACOR Marine Holdings
SMHI
$214M
$15M 0.54%
1,314,164
+121
+0% +$1.07K
JSPR icon
14
Jasper Therapeutics
JSPR
$24.8M
$11.8M 0.42%
876,189
– –
CUBE icon
15
CubeSmart
CUBE
$9.48B
$9.85M 0.35%
220,500
– –
SPRB
16
Spruce Biosciences
SPRB
$120M
$6.23M 0.22%
38,620
– –
ACET icon
17
Adicet Bio
ACET
$75.9M
$5.12M 0.18%
132,212
– –
SLNO
18
DELISTED
Soleno Therapeutics
SLNO
$5.09M 0.18%
1,201,506
– –
EM
19
DELISTED
Smart Share Global Ltd
EM
$4.69M 0.17%
4,810,209
– –
EFTR
20
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$3.95M 0.14%
192,885
– –
NCNA
21
NuCana
NCNA
$5.45M
$2.6M 0.09%
667
– –
PRTK
22
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$2.3M 0.08%
1,041,131
– –
XCUR icon
23
Exicure
XCUR
$10.7M
$369K 0.01%
56,327
– –
AIU
24
DELISTED
Meta Data Limited American Depositary Shares, each representing ten (10) Class A Ordinary Shares
AIU
$336K 0.01%
62,880
– –
SYRE icon
25
Spyre Therapeutics
SYRE
$8.7B
$108K ﹤0.01%
9,620
– –
1
2

Similar funds

SGA
Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $10.8B AUM 21.99% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $10.9B AUM 18.64% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

Carlyle Group's Q2 2023 Portfolio in Review

As of Q2 2023, Carlyle Group held 30 positions worth $2.81B, down 16% from $3.35B the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Carlyle Group withdrew a net $547M in Q2 2023, closing 4 positions and reducing 3 holdings. Its most notable exit was Vaxcyte, an estimated $72.1M position sold in full.

By sector, the portfolio is most concentrated in Technology at 48% of assets, down from 52% a quarter earlier, followed by Healthcare and Consumer Staples.

Against the trend, Carlyle Group added an estimated $6.48M to Phathom Pharmaceuticals.

  • Carlyle Group added most to Phathom Pharmaceuticals in Q2 2023, an estimated $6.48M increase.
  • Carlyle Group's biggest Q2 2023 reduction was MKS Inc, cutting an estimated $458M.
  • Carlyle Group fully exited Vaxcyte in Q2 2023, selling an estimated $72.1M.
  • Carlyle Group's ten largest holdings make up 96% of its $2.81B portfolio in Q2 2023.
  • Carlyle Group opened 0 new positions and closed 4 in Q2 2023.
  • Carlyle Group's portfolio value fell 16% quarter-over-quarter to $2.81B.

Based on Carlyle Group's 13F filing for Q2 2023, filed 4 Aug 2023.